Novartis AG ADR is a drug manufacturers - general business based in the US. Novartis AG ADR shares (NVS) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $133.72 – an increase of 2.51% over the previous week. Novartis AG ADR employs 75,883 staff and has a trailing 12-month revenue of around $56.4 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Novartis AG ADR stock price (NYSE: NVS)
Use our graph to track the performance of NVS stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Novartis AG ADR price performance over time
Historical closes compared with the close of $132.28 from 2025-12-02
1 week (2025-11-26)
1.41%
1 month (2025-11-04)
5.82%
3 months (2025-09-04)
3.01%
6 months (2025-06-04)
13.12%
1 year (2024-12-04)
29.89%
2 years (2023-12-04)
38.74%
3 years (2022-12-02)
68.70%
5 years (2020-12-04)
86.90%
Is Novartis AG ADR stock undervalued or overvalued?
Valuing Novartis AG ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis AG ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novartis AG ADR's P/E ratio
Novartis AG ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Novartis AG ADR shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Novartis AG ADR's PEG ratio
Novartis AG ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0543. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novartis AG ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novartis AG ADR's EBITDA
Novartis AG ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $24.9 billion.
The EBITDA is a measure of a Novartis AG ADR's overall financial performance and is widely used to measure a its profitability.
Novartis AG ADR financials
Revenue TTM
$56.4 billion
Operating margin TTM
31.93%
Gross profit TTM
$43 billion
Return on assets TTM
12.13%
Return on equity TTM
32.62%
Profit margin
25.53%
Book value
$23.10
Market Capitalization
$250.2 billion
TTM: trailing 12 months
Novartis AG ADR share dividends
Dividend payout ratio: 44.73% of net profits
Recently Novartis AG ADR has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novartis AG ADR shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Novartis AG ADR's case, that would currently equate to about $3.862 per share.
While Novartis AG ADR's payout ratio might seem fairly standard, it's worth remembering that Novartis AG ADR may be investing much of the rest of its net profits in future growth.
Novartis AG ADR's most recent dividend payout was on 24 April 2025. The latest dividend was paid out to all shareholders who bought their shares by 11 March 2025 (the "ex-dividend date").
Have Novartis AG ADR's shares ever split?
Novartis AG ADR's shares were
split on a 1116:1000 basis on 8 April 2019
. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1116 shares. This wouldn't directly have changed the overall worth of your Novartis AG ADR shares – just the quantity. However, indirectly, the new 10.4% lower share price could have impacted the market appetite for Novartis AG ADR shares which in turn could have impacted Novartis AG ADR's share price.
Novartis AG ADR share price volatility
Over the last 12 months, Novartis AG ADR's shares have ranged in value from as little as $92.7237 up to $134. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novartis AG ADR's is 0.439. This would suggest that Novartis AG ADR's shares are less volatile than average (for this exchange).
Novartis AG ADR overview
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Frequently asked questions
null What percentage of Novartis AG ADR is owned by insiders or institutions? Currently 0.002% of Novartis AG ADR shares are held by insiders and 7.127% by institutions.How many people work for Novartis AG ADR? Latest data suggests 75,883 work at Novartis AG ADR.When does the fiscal year end for Novartis AG ADR? Novartis AG ADR's fiscal year ends in December.Where is Novartis AG ADR based? Novartis AG ADR's address is: Lichtstrasse 35, Basel, Switzerland, 4056What is Novartis AG ADR's ISIN number? Novartis AG ADR's international securities identification number is: US66987V1098What is Novartis AG ADR's CUSIP number? Novartis AG ADR's Committee on Uniform Securities Identification Procedures number is: 66987V109
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
